Cat. No.: HY-N0372

Licochalcone A

19 Cited Publications

Customer Review

Based on 19 publication(s) in Google Scholar

Licochalcone A (LCA), a chalconoid, presents obvious anti-cancer effects, displays broad-spectrum inhibition against UDP-glucuronosyltransferases (UGTs). Licochalcone A (LCA) exhibits strong inhibitory effects against UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A9, and 2B7 (both IC₅₀ and K_i values lower than 5 μM) .

For research use only. We do not sell to patients.

Purity: 99.76%
CAS No.: 58749-22-7
Formula: C₂₁H₂₂O₄
Molecular Weight:338.40

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Licochalcone A Chemical Structure

CAS No.: 58749-22-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- Clinical Trial
Chemical Information
Publications (19)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Licochalcone A (LCA), a chalconoid, presents obvious anti-cancer effects, displays broad-spectrum inhibition against UDP-glucuronosyltransferases (UGTs)^[1]. Licochalcone A (LCA) exhibits strong inhibitory effects against UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A9, and 2B7 (both IC₅₀ and K_i values lower than 5 μM) ^[2].

Cellular Effect

Cell Line	Type	Value	Description	References
BV-2	IC₅₀	0.625 μg/mL Compound: 142	Antiinflammatory activity in LPS-induced mouse BV-2 cells assessed as reduction in COX-2 protein expression by Western blot analysis Antiinflammatory activity in LPS-induced mouse BV-2 cells assessed as reduction in COX-2 protein expression by Western blot analysis	[PMID: 37683361]
CHO-K1	IC₅₀	508.3 μM Compound: 118	Cytotoxicity against CHO-K1 cells incubated for 24 hrs by colorimetric assay Cytotoxicity against CHO-K1 cells incubated for 24 hrs by colorimetric assay	[PMID: 33479649]
Erythrocyte	IC₅₀	1.43 μg/mL Compound: 61	Antiplasmodial activity against mixture of chloroquine resistant Plasmodium falciparum RKL 303-chloroquine sensitive Plasmodium falciparum 3D7 infected in human erythrocyte assessed as inhibition of parasite growth incubated for 48 hrs by Giemsa staining Antiplasmodial activity against mixture of chloroquine resistant Plasmodium falciparum RKL 303-chloroquine sensitive Plasmodium falciparum 3D7 infected in human erythrocyte assessed as inhibition of parasite growth incubated for 48 hrs by Giemsa staining	[PMID: 35985254]
GES1	IC₅₀	>180 μM Compound: Licochalcone A	Cytotoxicity against human GES-1 cells Cytotoxicity against human GES-1 cells	[PMID: 32347726]
HEK293	IC₅₀	0.28 nM Compound: Licochalcone A	Effect on etoposide-induced cytotoxicity against HEK293 cells by measuring etoposide IC50 at 3 uM after 72 hrs by CCK8 assay (Rvb =0.21 +/- 0.04 uM) Effect on etoposide-induced cytotoxicity against HEK293 cells by measuring etoposide IC50 at 3 uM after 72 hrs by CCK8 assay (Rvb =0.21 +/- 0.04 uM)	[PMID: 32347726]
HEK293	IC₅₀	0.3 nM Compound: Licochalcone A	Effect on etoposide-induced cytotoxicity against HEK293 cells by measuring etoposide IC50 at 1 uM after 72 hrs by CCK8 assay (Rvb =0.21 +/- 0.04 uM) Effect on etoposide-induced cytotoxicity against HEK293 cells by measuring etoposide IC50 at 1 uM after 72 hrs by CCK8 assay (Rvb =0.21 +/- 0.04 uM)	[PMID: 32347726]
HEK293	IC₅₀	0.3 nM Compound: Licochalcone A	Effect on etoposide-induced cytotoxicity against HEK293 cells by measuring etoposide IC50 at 2 uM after 72 hrs by CCK8 assay (Rvb =0.21 +/- 0.04 uM) Effect on etoposide-induced cytotoxicity against HEK293 cells by measuring etoposide IC50 at 2 uM after 72 hrs by CCK8 assay (Rvb =0.21 +/- 0.04 uM)	[PMID: 32347726]
HEK293	IC₅₀	0.31 nM Compound: Licochalcone A	Effect on etoposide-induced cytotoxicity against HEK293 cells by measuring etoposide IC50 at 0.5 uM after 72 hrs by CCK8 assay (Rvb =0.21 +/- 0.04 uM) Effect on etoposide-induced cytotoxicity against HEK293 cells by measuring etoposide IC50 at 0.5 uM after 72 hrs by CCK8 assay (Rvb =0.21 +/- 0.04 uM)	[PMID: 32347726]
HEK293	IC₅₀	10 μM Compound: Licochalcone A	Cytotoxicity against HEK293 cells after 72 hrs by CCK8 assay Cytotoxicity against HEK293 cells after 72 hrs by CCK8 assay	[PMID: 32347726]
HEK293	IC₅₀	10 μM Compound: Licochalcone A	Cytotoxicity against HEK293 cells overexpressing human ABCG2 after 72 hrs by CCK8 assay Cytotoxicity against HEK293 cells overexpressing human ABCG2 after 72 hrs by CCK8 assay	[PMID: 32347726]
HEK293	IC₅₀	24.72 nM Compound: Licochalcone A	Effect on topotecan-induced cytotoxicity against HEK293 cells by measuring topotecan IC50 at 1 uM after 72 hrs by CCK8 assay (Rvb = 24.60 +/- 5.98 nM) Effect on topotecan-induced cytotoxicity against HEK293 cells by measuring topotecan IC50 at 1 uM after 72 hrs by CCK8 assay (Rvb = 24.60 +/- 5.98 nM)	[PMID: 32347726]
HEK293	IC₅₀	25.55 nM Compound: Licochalcone A	Effect on topotecan-induced cytotoxicity against HEK293 cells by measuring topotecan IC50 at 3 uM after 72 hrs by CCK8 assay (Rvb = 24.60 +/- 5.98 nM) Effect on topotecan-induced cytotoxicity against HEK293 cells by measuring topotecan IC50 at 3 uM after 72 hrs by CCK8 assay (Rvb = 24.60 +/- 5.98 nM)	[PMID: 32347726]
HEK293	IC₅₀	25.89 nM Compound: Licochalcone A	Effect on topotecan-induced cytotoxicity against HEK293 cells by measuring topotecan IC50 at 2 uM after 72 hrs by CCK8 assay (Rvb = 24.60 +/- 5.98 nM) Effect on topotecan-induced cytotoxicity against HEK293 cells by measuring topotecan IC50 at 2 uM after 72 hrs by CCK8 assay (Rvb = 24.60 +/- 5.98 nM)	[PMID: 32347726]
HEK293	IC₅₀	26.83 nM Compound: Licochalcone A	Effect on topotecan-induced cytotoxicity against HEK293 cells by measuring topotecan IC50 at 0.5 uM after 72 hrs by CCK8 assay (Rvb = 24.60 +/- 5.98 nM) Effect on topotecan-induced cytotoxicity against HEK293 cells by measuring topotecan IC50 at 0.5 uM after 72 hrs by CCK8 assay (Rvb = 24.60 +/- 5.98 nM)	[PMID: 32347726]
HEK293	IC₅₀	4.6 nM Compound: Licochalcone A	Effect on mitoxantrone-induced cytotoxicity against HEK293 cells by measuring mitoxantrone IC50 at 1 uM after 72 hrs by CCK8 assay (Rvb = 4.70 +/- 0.99 nM) Effect on mitoxantrone-induced cytotoxicity against HEK293 cells by measuring mitoxantrone IC50 at 1 uM after 72 hrs by CCK8 assay (Rvb = 4.70 +/- 0.99 nM)	[PMID: 32347726]
HEK293	IC₅₀	4.74 nM Compound: Licochalcone A	Effect on mitoxantrone-induced cytotoxicity against HEK293 cells by measuring mitoxantrone IC50 at 2 uM after 72 hrs by CCK8 assay (Rvb = 4.70 +/- 0.99 nM) Effect on mitoxantrone-induced cytotoxicity against HEK293 cells by measuring mitoxantrone IC50 at 2 uM after 72 hrs by CCK8 assay (Rvb = 4.70 +/- 0.99 nM)	[PMID: 32347726]
HEK293	IC₅₀	4.78 nM Compound: Licochalcone A	Effect on mitoxantrone-induced cytotoxicity against HEK293 cells by measuring mitoxantrone IC50 at 3 uM after 72 hrs by CCK8 assay (Rvb = 4.70 +/- 0.99 nM) Effect on mitoxantrone-induced cytotoxicity against HEK293 cells by measuring mitoxantrone IC50 at 3 uM after 72 hrs by CCK8 assay (Rvb = 4.70 +/- 0.99 nM)	[PMID: 32347726]
HEK293	IC₅₀	5.11 nM Compound: Licochalcone A	Effect on mitoxantrone-induced cytotoxicity against HEK293 cells by measuring mitoxantrone IC50 at 0.5 uM after 72 hrs by CCK8 assay (Rvb = 4.70 +/- 0.99 nM) Effect on mitoxantrone-induced cytotoxicity against HEK293 cells by measuring mitoxantrone IC50 at 0.5 uM after 72 hrs by CCK8 assay (Rvb = 4.70 +/- 0.99 nM)	[PMID: 32347726]
HEK293	IC₅₀	7.99 nM Compound: Licochalcone A	Effect on Colchicine-induced cytotoxicity against HEK293 cells by measuring colchicine IC50 at 1 uM after 72 hrs by CCK8 assay (Rvb = 8.42 +/- 3 nM) Effect on Colchicine-induced cytotoxicity against HEK293 cells by measuring colchicine IC50 at 1 uM after 72 hrs by CCK8 assay (Rvb = 8.42 +/- 3 nM)	[PMID: 32347726]
HEK293	IC₅₀	8.67 nM Compound: Licochalcone A	Effect on Colchicine-induced cytotoxicity against HEK293 cells by measuring colchicine IC50 at 0.5 uM after 72 hrs by CCK8 assay (Rvb = 8.42 +/- 3 nM) Effect on Colchicine-induced cytotoxicity against HEK293 cells by measuring colchicine IC50 at 0.5 uM after 72 hrs by CCK8 assay (Rvb = 8.42 +/- 3 nM)	[PMID: 32347726]
HEK293	IC₅₀	8.9 nM Compound: Licochalcone A	Effect on Colchicine-induced cytotoxicity against HEK293 cells by measuring colchicine IC50 at 2 uM after 72 hrs by CCK8 assay (Rvb = 8.42 +/- 3 nM) Effect on Colchicine-induced cytotoxicity against HEK293 cells by measuring colchicine IC50 at 2 uM after 72 hrs by CCK8 assay (Rvb = 8.42 +/- 3 nM)	[PMID: 32347726]
HEK293	IC₅₀	9.03 nM Compound: Licochalcone A	Effect on Colchicine-induced cytotoxicity against HEK293 cells by measuring colchicine IC50 at 3 uM after 72 hrs by CCK8 assay (Rvb = 8.42 +/- 3 nM) Effect on Colchicine-induced cytotoxicity against HEK293 cells by measuring colchicine IC50 at 3 uM after 72 hrs by CCK8 assay (Rvb = 8.42 +/- 3 nM)	[PMID: 32347726]
HEK-293T	IC₅₀	4.2 μg/mL Compound: 2	Inhibition of oseltamivir-resistant H1N1 swine influenza virus neuraminidase H274Y mutant activity expressed in HEK293T cells after 2 hrs by spectrofluorometry Inhibition of oseltamivir-resistant H1N1 swine influenza virus neuraminidase H274Y mutant activity expressed in HEK293T cells after 2 hrs by spectrofluorometry	[PMID: 21123068]
HEK-293T	IC₅₀	5.42 μg/mL Compound: 2	Inhibition of wild type H1N1 swine influenza virus neuraminidase activity expressed in HEK293T cells after 2 hrs by spectrofluorometry Inhibition of wild type H1N1 swine influenza virus neuraminidase activity expressed in HEK293T cells after 2 hrs by spectrofluorometry	[PMID: 21123068]
HeLa	IC₅₀	48.5 μM Compound: 4	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31539776]
Hepatocyte	IC₅₀	0.927 nM Compound: Licochalcone A	Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs	[PMID: 18212104]
HK-2	IC₅₀	88.7 μM Compound: 4	Cytotoxicity against human HK2 cells assessed as reduction in cell viability after 24 to 48 hrs by MTT assay Cytotoxicity against human HK2 cells assessed as reduction in cell viability after 24 to 48 hrs by MTT assay	[PMID: 31539776]
HT-1080	IC₅₀	10.75 μM Compound: Licochalcone A	Antiproliferative activity against human HT1080 cells harboring IDH1-R132C mutation incubated for 48 hrs Antiproliferative activity against human HT1080 cells harboring IDH1-R132C mutation incubated for 48 hrs	[PMID: 31836442]
MCF7	IC₅₀	22 μM Compound: 4	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 to 48 hrs by MTS assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 to 48 hrs by MTS assay	[PMID: 31539776]
MDA-MB-231	IC₅₀	22 μM Compound: 4	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 to 48 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 to 48 hrs by MTS assay	[PMID: 31539776]
MSTO-211H	IC₅₀	26 μM Compound: 4	Cytotoxicity against human MSTO-211H cells assessed as reduction in cell viability after 24 to 48 hrs by MTS assay Cytotoxicity against human MSTO-211H cells assessed as reduction in cell viability after 24 to 48 hrs by MTS assay	[PMID: 31539776]
NCI-H28	IC₅₀	30 μM Compound: 4	Cytotoxicity against human NCI-H28 cells assessed as reduction in cell viability after 24 to 48 hrs by MTS assay Cytotoxicity against human NCI-H28 cells assessed as reduction in cell viability after 24 to 48 hrs by MTS assay	[PMID: 31539776]
NCI-H460	IC₅₀	10 μM Compound: Licochalcone A	Cytotoxicity against human H460 cells after 72 hrs by MTT assay Cytotoxicity against human H460 cells after 72 hrs by MTT assay	[PMID: 32347726]
NCI-H460	IC₅₀	19.84 nM Compound: Licochalcone A	Effect on mitoxantrone-induced cytotoxicity against human H460 cells by measuring mitoxantrone IC50 at 1 uM after 72 hrs by MTT assay (Rvb = 21.61 +/- 5.85 nM) Effect on mitoxantrone-induced cytotoxicity against human H460 cells by measuring mitoxantrone IC50 at 1 uM after 72 hrs by MTT assay (Rvb = 21.61 +/- 5.85 nM)	[PMID: 32347726]
NCI-H460	IC₅₀	20.1 nM Compound: Licochalcone A	Effect on mitoxantrone-induced cytotoxicity against human H460 cells by measuring mitoxantrone IC50 at 2 uM after 72 hrs by MTT assay (Rvb = 21.61 +/- 5.85 nM) Effect on mitoxantrone-induced cytotoxicity against human H460 cells by measuring mitoxantrone IC50 at 2 uM after 72 hrs by MTT assay (Rvb = 21.61 +/- 5.85 nM)	[PMID: 32347726]
NCI-H460	IC₅₀	20.34 nM Compound: Licochalcone A	Effect on mitoxantrone-induced cytotoxicity against human H460 cells by measuring mitoxantrone IC50 at 3 uM after 72 hrs by MTT assay (Rvb = 21.61 +/- 5.85 nM) Effect on mitoxantrone-induced cytotoxicity against human H460 cells by measuring mitoxantrone IC50 at 3 uM after 72 hrs by MTT assay (Rvb = 21.61 +/- 5.85 nM)	[PMID: 32347726]
NCI-H460	IC₅₀	21.69 nM Compound: Licochalcone A	Effect on topotecan-induced cytotoxicity against human H460 cells by measuring topotecan IC50 at 2 uM after 72 hrs by MTT assay (Rvb = 37.42 +/- 5.45 nM) Effect on topotecan-induced cytotoxicity against human H460 cells by measuring topotecan IC50 at 2 uM after 72 hrs by MTT assay (Rvb = 37.42 +/- 5.45 nM)	[PMID: 32347726]
NCI-H460	IC₅₀	22.41 nM Compound: Licochalcone A	Effect on topotecan-induced cytotoxicity against human H460 cells by measuring topotecan IC50 at 1 uM after 72 hrs by MTT assay (Rvb = 37.42 +/- 5.45 nM) Effect on topotecan-induced cytotoxicity against human H460 cells by measuring topotecan IC50 at 1 uM after 72 hrs by MTT assay (Rvb = 37.42 +/- 5.45 nM)	[PMID: 32347726]
NCI-H460	IC₅₀	22.52 nM Compound: Licochalcone A	Effect on topotecan-induced cytotoxicity against human H460 cells by measuring topotecan IC50 at 3 uM after 72 hrs by MTT assay (Rvb = 37.42 +/- 5.45 nM) Effect on topotecan-induced cytotoxicity against human H460 cells by measuring topotecan IC50 at 3 uM after 72 hrs by MTT assay (Rvb = 37.42 +/- 5.45 nM)	[PMID: 32347726]
NCI-H460	IC₅₀	25.54 nM Compound: Licochalcone A	Effect on topotecan-induced cytotoxicity against human H460 cells by measuring topotecan IC50 at 0.5 uM after 72 hrs by MTT assay (Rvb = 37.42 +/- 5.45 nM) Effect on topotecan-induced cytotoxicity against human H460 cells by measuring topotecan IC50 at 0.5 uM after 72 hrs by MTT assay (Rvb = 37.42 +/- 5.45 nM)	[PMID: 32347726]
NCI-H460	IC₅₀	25.91 nM Compound: Licochalcone A	Effect on mitoxantrone-induced cytotoxicity against human H460 cells by measuring mitoxantrone IC50 at 0.5 uM after 72 hrs by MTT assay (Rvb = 21.61 +/- 5.85 nM) Effect on mitoxantrone-induced cytotoxicity against human H460 cells by measuring mitoxantrone IC50 at 0.5 uM after 72 hrs by MTT assay (Rvb = 21.61 +/- 5.85 nM)	[PMID: 32347726]
RBL-2H3	IC₅₀	17 μM Compound: LicoA	Antiinflammatory activity in RBL2H3 cells assessed as inhibition of degranulation Antiinflammatory activity in RBL2H3 cells assessed as inhibition of degranulation	[PMID: 24316124]
S1	IC₅₀	10 μM Compound: Licochalcone A	Cytotoxicity against human S1 cells after 72 hrs by MTT assay Cytotoxicity against human S1 cells after 72 hrs by MTT assay	[PMID: 32347726]
S1	IC₅₀	10.7 nM Compound: Licochalcone A	Effect on topotecan-induced cytotoxicity against human S1 cells by measuring topotecan IC50 at 2 uM after 72 hrs by CCK8 assay (Rvb = 9.21 +/- 1.45 nM) Effect on topotecan-induced cytotoxicity against human S1 cells by measuring topotecan IC50 at 2 uM after 72 hrs by CCK8 assay (Rvb = 9.21 +/- 1.45 nM)	[PMID: 32347726]
S1	IC₅₀	11.01 nM Compound: Licochalcone A	Effect on topotecan-induced cytotoxicity against human S1 cells by measuring topotecan IC50 at 1 uM after 72 hrs by CCK8 assay (Rvb = 9.21 +/- 1.45 nM) Effect on topotecan-induced cytotoxicity against human S1 cells by measuring topotecan IC50 at 1 uM after 72 hrs by CCK8 assay (Rvb = 9.21 +/- 1.45 nM)	[PMID: 32347726]
S1	IC₅₀	11.74 nM Compound: Licochalcone A	Effect on topotecan-induced cytotoxicity against human S1 cells by measuring topotecan IC50 at 3 uM after 72 hrs by CCK8 assay (Rvb = 9.21 +/- 1.45 nM) Effect on topotecan-induced cytotoxicity against human S1 cells by measuring topotecan IC50 at 3 uM after 72 hrs by CCK8 assay (Rvb = 9.21 +/- 1.45 nM)	[PMID: 32347726]
S1	IC₅₀	4.44 nM Compound: Licochalcone A	Effect on mitoxantrone-induced cytotoxicity against human S1 cells by measuring mitoxantrone IC50 at 0.5 uM after 72 hrs by MTT assay (Rvb = 4.83 +/- 0.83 nM) Effect on mitoxantrone-induced cytotoxicity against human S1 cells by measuring mitoxantrone IC50 at 0.5 uM after 72 hrs by MTT assay (Rvb = 4.83 +/- 0.83 nM)	[PMID: 32347726]
S1	IC₅₀	4.53 nM Compound: Licochalcone A	Effect on mitoxantrone-induced cytotoxicity against human S1 cells by measuring mitoxantrone IC50 at 1 uM after 72 hrs by CCK8 assay (Rvb = 4.83 +/- 0.83 nM) Effect on mitoxantrone-induced cytotoxicity against human S1 cells by measuring mitoxantrone IC50 at 1 uM after 72 hrs by CCK8 assay (Rvb = 4.83 +/- 0.83 nM)	[PMID: 32347726]
S1	IC₅₀	4.55 nM Compound: Licochalcone A	Effect on mitoxantrone-induced cytotoxicity against human S1 cells by measuring mitoxantrone IC50 at 2 uM after 72 hrs by CCK8 assay (Rvb = 4.83 +/- 0.83 nM) Effect on mitoxantrone-induced cytotoxicity against human S1 cells by measuring mitoxantrone IC50 at 2 uM after 72 hrs by CCK8 assay (Rvb = 4.83 +/- 0.83 nM)	[PMID: 32347726]
S1	IC₅₀	4.73 nM Compound: Licochalcone A	Effect on mitoxantrone-induced cytotoxicity against human S1 cells by measuring mitoxantrone IC50 at 3 uM after 72 hrs by CCK8 assay (Rvb = 4.83 +/- 0.83 nM) Effect on mitoxantrone-induced cytotoxicity against human S1 cells by measuring mitoxantrone IC50 at 3 uM after 72 hrs by CCK8 assay (Rvb = 4.83 +/- 0.83 nM)	[PMID: 32347726]
S1	IC₅₀	9.73 nM Compound: Licochalcone A	Effect on topotecan-induced cytotoxicity against human S1 cells by measuring topotecan IC50 at 0.5 uM after 72 hrs by MTT assay (Rvb = 9.21 +/- 1.45 nM) Effect on topotecan-induced cytotoxicity against human S1 cells by measuring topotecan IC50 at 0.5 uM after 72 hrs by MTT assay (Rvb = 9.21 +/- 1.45 nM)	[PMID: 32347726]
S1-M1-80	IC₅₀	0.31 μM Compound: Licochalcone A	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as effect on topotecan-induced cytotoxicity by measuring topotecan IC50 at 3 uM after 72 hrs by MTT assay (Rvb = 10.14 +/- 2.820 uM) Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as effect on topotecan-induced cytotoxicity by measuring topotecan IC50 at 3 uM after 72 hrs by MTT assay (Rvb = 10.14 +/- 2.820 uM)	[PMID: 32347726]
S1-M1-80	IC₅₀	0.41 μM Compound: Licochalcone A	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as effect on topotecan-induced cytotoxicity by measuring topotecan IC50 at 2 uM after 72 hrs by MTT assay (Rvb = 10.14 +/- 2.820 uM) Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as effect on topotecan-induced cytotoxicity by measuring topotecan IC50 at 2 uM after 72 hrs by MTT assay (Rvb = 10.14 +/- 2.820 uM)	[PMID: 32347726]
S1-M1-80	IC₅₀	0.61 μM Compound: Licochalcone A	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as effect on topotecan-induced cytotoxicity by measuring topotecan IC50 at 1 uM after 72 hrs by MTT assay (Rvb = 10.14 +/- 2.820 uM) Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as effect on topotecan-induced cytotoxicity by measuring topotecan IC50 at 1 uM after 72 hrs by MTT assay (Rvb = 10.14 +/- 2.820 uM)	[PMID: 32347726]
S1-M1-80	IC₅₀	1.03 μM Compound: Licochalcone A	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as effect on topotecan-induced cytotoxicity by measuring topotecan IC50 at 0.5 uM after 72 hrs by MTT assay (Rvb = 10.14 +/- 2.820 uM) Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as effect on topotecan-induced cytotoxicity by measuring topotecan IC50 at 0.5 uM after 72 hrs by MTT assay (Rvb = 10.14 +/- 2.820 uM)	[PMID: 32347726]
S1-M1-80	IC₅₀	1.53 μM Compound: Licochalcone A	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as effect on mitoxantrone-induced cytotoxicity by measuring mitoxantrone IC50 at 3 uM after 72 hrs by MTT assay (Rvb = 73.62 +/- 7.20 uM) Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as effect on mitoxantrone-induced cytotoxicity by measuring mitoxantrone IC50 at 3 uM after 72 hrs by MTT assay (Rvb = 73.62 +/- 7.20 uM)	[PMID: 32347726]
S1-M1-80	IC₅₀	10 μM Compound: Licochalcone A	Cytotoxicity against human S1-M1-80 cells harboring ABCG2 (unknown origin) after 72 hrs by MTT assay Cytotoxicity against human S1-M1-80 cells harboring ABCG2 (unknown origin) after 72 hrs by MTT assay	[PMID: 32347726]
S1-M1-80	IC₅₀	2.63 μM Compound: Licochalcone A	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as effect on mitoxantrone-induced cytotoxicity by measuring mitoxantrone IC50 at 2 uM after 72 hrs by MTT assay (Rvb = 73.62 +/- 7.20 uM) Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as effect on mitoxantrone-induced cytotoxicity by measuring mitoxantrone IC50 at 2 uM after 72 hrs by MTT assay (Rvb = 73.62 +/- 7.20 uM)	[PMID: 32347726]
S1-M1-80	IC₅₀	39.47 μM Compound: Licochalcone A	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as effect on mitoxantrone-induced cytotoxicity by measuring mitoxantrone IC50 at 0.5 uM after 72 hrs by MTT assay (Rvb = 73.62 +/- 7.20 uM) Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as effect on mitoxantrone-induced cytotoxicity by measuring mitoxantrone IC50 at 0.5 uM after 72 hrs by MTT assay (Rvb = 73.62 +/- 7.20 uM)	[PMID: 32347726]
S1-M1-80	IC₅₀	6.8 μM Compound: Licochalcone A	Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as effect on mitoxantrone-induced cytotoxicity by measuring mitoxantrone IC50 at 1 uM after 72 hrs by MTT assay (Rvb = 73.62 +/- 7.20 uM) Reversal of ABCG2 (unknown origin)-mediated multidrug resistance in human S1-M1-80 cells assessed as effect on mitoxantrone-induced cytotoxicity by measuring mitoxantrone IC50 at 1 uM after 72 hrs by MTT assay (Rvb = 73.62 +/- 7.20 uM)	[PMID: 32347726]
SiHa	IC₅₀	42.2 μM Compound: 4	Cytotoxicity against human SiHa cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human SiHa cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31539776]
U-87MG ATCC	IC₅₀	>50 μM Compound: Licochalcone A	Cytotoxicity against human U87MG cells harboring wild type IDH1 incubated for 48 hrs Cytotoxicity against human U87MG cells harboring wild type IDH1 incubated for 48 hrs	[PMID: 31836442]
WI-38	IC₅₀	90.2 μM Compound: 4	Cytotoxicity against human WI38 cells assessed as reduction in cell viability after 24 to 48 hrs by MTT assay Cytotoxicity against human WI38 cells assessed as reduction in cell viability after 24 to 48 hrs by MTT assay	[PMID: 31539776]

In Vitro

Licochalcone A (LCA) exhibits strong inhibitory effects against UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A9, and 2B7 (both IC₅₀ and K_i values lower than 5 μM)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 58749-22-7
Appearance Solid
Molecular Weight 338.40
Formula C₂₁H₂₂O₄
Color Yellow to orange
SMILES

O=C(C1=CC=C(O)C=C1)/C=C/C2=CC(C(C)(C)C=C)=C(O)C=C2OC
Structure Classification
- Flavonoids
- Chalcones
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (19)

All Bio/Physico-chemical AssayWBCell Proliferation/Viability AssayIn Vivo Efficacy StudyIHC

Sort by:

Journal Impact Factor

Exploration (Beijing)

STIP1 drives Metabolic Reprogramming in Esophageal Squamous Cell Carcinoma via AHCY-LDHA Axis. [Abstract]

2025 May 25;5(5):20240198. PMID: 41163796

Licochalcone A purchased from MedChemExpress. Usage Cited in: Exploration (Beijing). 2025 May 25;5(5):20240198. [Abstract]

SPR analysis verifies direct binding between LCA and STIP1. Sensorgram shows response over time as Licochalcone A (LCA; 0.6215, 1.25, 2.5, 5, 10, 20 μM) passes over STIP1-conjugated chip.

Licochalcone A purchased from MedChemExpress. Usage Cited in: Exploration (Beijing). 2025 May 25;5(5):20240198. [Abstract]

After treat various doses of Licochalcone A (LCA; 0, 0.5, 5, 10 μM) , AHCY, LDHA, PKM2 and ALDOA protein level were measured by western blot in KYSE30, KYSE450 cells.

Licochalcone A purchased from MedChemExpress. Usage Cited in: Exploration (Beijing). 2025 May 25;5(5):20240198. [Abstract]

Licochalcone A (LCA; 0, 10 μM) decreased glucose consumption, lactate secretion in KYSE30, KYSE450 cells.

Licochalcone A purchased from MedChemExpress. Usage Cited in: Exploration (Beijing). 2025 May 25;5(5):20240198. [Abstract]

Licochalcone A (LCA; 0, 10 μM) decreased ECAR reflective of glycolytic flux in KYSE30 cells, reflecting impaired glycolysis.

Licochalcone A purchased from MedChemExpress. Usage Cited in: Exploration (Beijing). 2025 May 25;5(5):20240198. [Abstract]

Licochalcone A (LCA; 0, 0.5， 5，10 μM； 24, 48, 72 h) dose-dependently reduces ESCC cell proliferation by MTT assay.

Licochalcone A purchased from MedChemExpress. Usage Cited in: Exploration (Beijing). 2025 May 25;5(5):20240198. [Abstract]

Licochalcone A (LCA； 10, 20 mg/kg; po; four times per week) for in 6‐week‐old female NOD/SCID mice ( fresh surgical ESCC tissues) significantly decreased tumor volumes and weights in two ESCC PDX models.

Licochalcone A purchased from MedChemExpress. Usage Cited in: Exploration (Beijing). 2025 May 25;5(5):20240198. [Abstract]

Licochalcone A (LCA; 10, 20 mg/kg; po; four times per week) for in 6‐week‐old female NOD/SCID mice ( fresh surgical ESCC tissues) decreased proliferation marker Ki67 and increased apoptosis marker Bax of of PDX tumors.
Acta Pharm Sin B

Chrysin serves as a novel inhibitor of DGK α/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC). [Abstract]

2021 Jan;11(1):143-155. PMID: 33532186
Phytomedicine

Licochalcone A promotes SP1/DNA-PKcs-dependent NHEJ repair to prevent ferroptosis and attenuate hepatic ischemia-reperfusion injury. [Abstract]

2025 Dec 3:150:157650. PMID: 41365195
Phytomedicine

Amoebicidal action of isoliquiritigenin and glabridin from Glycyrrhiza species: Mechanisms and effects against Acanthamoeba castellanii. [Abstract]

2025 Sep:145:157081. PMID: 40701128
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
Phytother Res

Syringin Protects Against Doxorubicin-Induced Cardiotoxicity via Apelinr-Dependent Activation of the Nuclear Factor-Erythroid 2-Related Factor 2/Heme Oxygenase-1 Antioxidant Pathway. [Abstract]

2026 Mar 26. PMID: 41883153
EMBO Rep

Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7-NLRP3 interaction. [Abstract]

2022 Feb 3;23(2):e53499. PMID: 34882936
J Ethnopharmacol

Licochalcone A promotes autophagy to ameliorate NAFLD by inhibiting the mTOR and regulating ULK1/Beclin1/VPS34 pathway. [Abstract]

2025 Jul 29:120333. PMID: 40744422
Biomolecules

Licochalcone A as a Potential Anti- Toxoplasma Agent: A Target Identification and Pharmacokinetic Study. [Abstract]

2026 Mar 10;16(3):410. PMID: 41897346
Biomolecules

Licochalcone E, a β-Amyloid Aggregation Inhibitor, Regulates Microglial M1/M2 Polarization via Inhibition of CTL1-Mediated Choline Uptake. [Abstract]

2023 Jan 17;13(2):191. PMID: 36830561
Eur J Pharmacol

Licochalcone A induces mitochondria-dependent apoptosis and interacts with venetoclax in acute myeloid leukemia. [Abstract]

2024 Apr 5:968:176418. PMID: 38350590
Sci Rep

Exploring the neuroprotective potential of Nrf2-pathway activators against annonacin toxicity. [Abstract]

2024 Aug 29;14(1):20123. PMID: 39209951
ACS Infect Dis

Licochalcone A Ameliorates Aspergillus fumigatus Keratitis by Reducing Fungal Load and Activating the Nrf2/HO-1 Signaling Pathway. [Abstract]

2024 Oct 11;10(10):3516-3527. PMID: 39283729
Integr Cancer Ther

Licochalcone A Induces Ferroptosis in Hepatocellular Carcinoma via Reactive Oxygen Species Activated by the SLC7A11/GPX4 Pathway. [Abstract]

2023 Jan-Dec:22:15347354231210867. PMID: 37965730
Onco Targets Ther

ERK Activation-Mediated Autophagy Induction Resists Licochalcone A-Induced Anticancer Activities in Lung Cancer Cells in vitro. [Abstract]

2021 Jan 8:13:13437-13450. PMID: 33447049
Exp Eye Res

Licochalcone A alleviates laser-induced choroidal neovascularization by inhibiting the endothelial-mesenchymal transition via PI3K/AKT signaling pathway. [Abstract]

2023 Jan:226:109335. PMID: 36436569
World Neurosurg

Activated Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Signal and Suppressed Autophagy Participate in Protection Offered by Licochalcone A Against Amyloid-β Peptide Fragment 25-35-Induced Injury in SH-SY5Y Cells. [Abstract]

2022 Jan:157:e390-e400. PMID: 34662660
bioRxiv

2025 Feb 19.
bioRxiv

2024 May 21.

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL (369.39 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9551 mL

14.7754 mL

29.5508 mL

5 mM

0.5910 mL

2.9551 mL

5.9102 mL

10 mM

0.2955 mL

1.4775 mL

2.9551 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.08 mg/mL (6.15 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (6.15 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Tang ZH, et al. Induction of C/EBP homologous protein-mediated apoptosis and autophagy by licochalcone A in non-small cell lung cancer cells. Sci Rep. 2016 May 17;6:26241.. . . . [Content Brief]

[2]. Tang ZH, et al. Induction of C/EBP homologous protein-mediated apoptosis and autophagy by licochalcone A in non-small cell lung cancer cells. Sci Rep. 2016 May 17;6:26241.. . . . [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9551 mL	14.7754 mL	29.5508 mL	73.8771 mL
	5 mM	0.5910 mL	2.9551 mL	5.9102 mL	14.7754 mL
	10 mM	0.2955 mL	1.4775 mL	2.9551 mL	7.3877 mL
	15 mM	0.1970 mL	0.9850 mL	1.9701 mL	4.9251 mL
	20 mM	0.1478 mL	0.7388 mL	1.4775 mL	3.6939 mL
	25 mM	0.1182 mL	0.5910 mL	1.1820 mL	2.9551 mL
	30 mM	0.0985 mL	0.4925 mL	0.9850 mL	2.4626 mL
	40 mM	0.0739 mL	0.3694 mL	0.7388 mL	1.8469 mL
	50 mM	0.0591 mL	0.2955 mL	0.5910 mL	1.4775 mL
	60 mM	0.0493 mL	0.2463 mL	0.4925 mL	1.2313 mL
	80 mM	0.0369 mL	0.1847 mL	0.3694 mL	0.9235 mL
	100 mM	0.0296 mL	0.1478 mL	0.2955 mL	0.7388 mL

Keywords

Licochalcone A

19 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Licochalcone A

MCE Bioactive Compound Library

Natural Product Library Plus

Clinical Compound Library Plus

Publications Citing Use of MedChemExpress (MCE) Licochalcone A

Biological Activity

Chemical Information

Publications (19)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Licochalcone A

MCE Bioactive Compound Library

Natural Product Library Plus

Clinical Compound Library Plus

Publications Citing Use of MedChemExpress (MCE) Licochalcone A

Biological Activity

Chemical Information

Publications (19)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Licochalcone A Related Classifications

Cat. No.: HY-N0372